Acute kidney injury, or AKI, affects a substantial share of hospitalized patients and carries significant short-term mortality and long-term risk of chronic kidney disease. At the cellular level, the damage concentrates in the proximal tubular epithelial cells, the workhorse cells of the nephron that normally rely overwhelmingly on mitochondrial oxidative phosphorylation to power massive reabsorption of solutes. When ischemia cuts off oxygen, these cells suffer a bioenergetic collapse: ATP production plummets, mitochondrial homeostasis is disrupted, and the tricarboxylic acid cycle, the central hub of oxidative metabolism, grinds toward inactivity. In a desperate bid to survive, the cells pivot to glycolysis, generating ATP from glucose without oxygen. That metabolic switch produces lactate as its signature byproduct, and lactate accumulation has long been regarded as a passive marker of the injury. The new study asks a sharper question: is lactate merely a bystander, or is it an active driver of the mitochondrial failure that follows?

To answer it, the researchers assembled evidence from three complementary systems: human renal biopsy specimens from patients with AKI, a murine model of ischemia/reperfusion-induced AKI, and proximal tubular epithelial cells challenged in vitro with hypoxia followed by reoxygenation. Across all three, they documented the same sequence. Ischemia/reperfusion inflicted a pronounced bioenergetic deficit in the proximal tubules, characterized by disrupted mitochondrial homeostasis, suppressed activity of TCA cycle genes, and enhanced aerobic glycolysis. Crucially, the lactate that accumulated during reperfusion was not inert. When the team blocked lactate production with sodium oxamate, a well-established inhibitor of lactate dehydrogenase, tubular injury was attenuated and oxidative metabolism was partially restored, indicating that lactate actively impairs mitochondrial oxidative metabolism rather than simply reflecting it.

The mechanistic trail then led to an unexpected player: MRS2, the mitochondrial RNA splicing 2 protein, which functions as the dominant channel for magnesium uptake into mitochondria. In the patient biopsies, serum lactate levels were positively correlated with renal MRS2 expression, hinting that the metabolic waste product and the magnesium channel were linked in human disease. Follow-up experiments in cells and mice confirmed the connection. Lactate accumulation increased mitochondrial magnesium uptake in an MRS2-dependent manner, driving an overload of magnesium ions inside the organelles. That overload, the study found, inhibits citrate synthase, the enzyme that catalyzes the first committed step of the TCA cycle. The consequence is a vicious loop: glycolysis generates lactate, lactate triggers MRS2-mediated magnesium influx, magnesium excess throttles the TCA cycle, and the crippled oxidative machinery forces the cell to lean even harder on glycolysis, producing more lactate.

Technical measurements anchored the claim. The team assessed mitochondrial function and oxidative metabolism using oxygen consumption rate assays, which quantify how efficiently mitochondria consume oxygen to generate ATP, alongside direct measurements of ATP production, mitochondrial membrane potential, and expression of TCA cycle genes. In the injured tubules, these readouts collapsed in parallel with rising lactate and rising MRS2 activity. When MRS2 was suppressed, either pharmacologically with the inhibitor CPACC or genetically with siRNA, mitochondrial oxidative metabolism rebounded, lactate accumulation fell, and renal injury following ischemia/reperfusion was attenuated. The genetic approach was delivered in vivo using lipid nanoparticles, the same class of delivery vehicles that carried mRNA vaccines into clinical use, encapsulating siMRS2 and silencing the channel in kidney tissue.

The therapeutic implications are striking because MRS2 offers a defined molecular handle on a process that has resisted intervention. Current management of ischemic AKI remains largely supportive, centered on hemodynamic optimization, avoidance of nephrotoxins, and, in severe cases, dialysis, while the underlying metabolic failure runs its course. A metabolism-based strategy that interrupts the lactate–MRS2 axis could, in principle, preserve mitochondrial function during the vulnerable reperfusion window and prevent the transition from reversible injury to established organ damage. The lipid nanoparticle delivery of siMRS2 demonstrated in this study provides a proof of concept that the target is druggable in living animals, and CPACC offers a small-molecule starting point for medicinal chemistry.

The study also reframes lactate itself. Long treated as a metabolic waste product or, in the Warburg tradition of cancer biology, as a hallmark of deranged metabolism, lactate is increasingly recognized as a signaling molecule with receptor-mediated and epigenetic effects. This work adds a subcellular dimension to that picture: lactate acting on the mitochondrial magnesium channel to reshape bioenergetics from within. In the kidney, where proximal tubular cells have minimal glycolytic capacity relative to their oxidative demands, such signaling may be particularly consequential, explaining why the glycolytic shift that sustains other cell types during hypoxia becomes maladaptive in the tubule.

Important caveats remain. The findings derive from biopsy specimens, a mouse model, and cell culture, and the translation of MRS2 inhibition to human therapy will require safety evaluation, since mitochondrial magnesium handling is fundamental to organelle function throughout the body. The timing of any intervention also matters, because reperfusion injury unfolds over hours and the therapeutic window must be defined precisely. The authors note that the article was shared early as a citable, peer-reviewed accepted version subject to further edits, and the work was supported by the National Natural Science Foundation of China, the National Key Research and Development Program of China, and Shanghai municipal science programs. Corresponding authors Yiqin Shi, Xiaoqiang Ding, and Nana Song led the collaboration, with Zhixin Yan, Annan Chen, and Fang Li as co-first authors.

Even with those qualifications, the study delivers a coherent and clinically resonant mechanism: hypoxia-driven lactate overproduction sustains maladaptive metabolic reprogramming through MRS2-dependent mitochondrial magnesium overload and citrate synthase inhibition. It explains why the kidney’s metabolic switch after ischemia becomes a trap rather than a rescue, and it converts that explanation into testable targets. If subsequent work confirms that blunting the lactate–MRS2 pathway protects human kidneys during surgery, transplantation, and shock, the humble end product of glycolysis may graduate from biomarker to bullseye, and the mitochondria of the proximal tubule may finally get the chance to resume the oxidative work upon which the entire organ depends.

Subject of Research: The lactate–MRS2 pathway driving maladaptive metabolic reprogramming in ischemia/reperfusion-induced acute kidney injury

Article Title: Lactate drives maladaptive metabolic reprogramming via MRS2 in ischemia/reperfusion-induced acute kidney injury

Article References: Yan, Z., Chen, A., Li, F., Zhang, J., Xie, Q., Han, G., Zhou, W., Yusufu, A., Chen, W., Gu, Q., Zhao, S., Yang, Y., Wang, J., Fang, Y., Li, Y., Dai, Y., Jin, S., Shi, Y., Ding, X., & Song, N. (2026). Lactate drives maladaptive metabolic reprogramming via MRS2 in ischemia/reperfusion-induced acute kidney injury. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06402-y

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06402-y

Keywords: acute kidney injury, ischemia/reperfusion, lactate, MRS2, mitochondrial magnesium overload, metabolic reprogramming, citrate synthase, proximal tubular epithelial cells, TCA cycle, lipid nanoparticle siRNA, mitochondrial dysfunction, sodium oxamate

Acute kidney injury, often precipitated by nephrotoxins—substances toxic to the kidney—poses a dire threat worldwide, especially among patients undergoing chemotherapy, antibiotic treatments, or those with exposure to environmental toxins. The kidney’s inability to effectively recover from injury leads to a cascade of detrimental effects, including chronic kidney disease and eventual renal failure. However, the body’s intrinsic mechanisms to mitigate such damage have remained elusive until now, with ELMO1 emerging as a key player.

Efferocytosis, the cellular process by which apoptotic cells are swiftly and safely cleared by phagocytes, has garnered increasing attention for its role in maintaining tissue homeostasis and limiting inflammation. The recent findings demonstrate that ELMO1, a crucial regulator of efferocytosis, orchestrates the clearance of dying cells within the renal microenvironment, thereby shielding the kidney from the secondary injury often triggered by unresolved cellular debris and ensuing inflammation.

Through meticulous in vivo and in vitro experiments, the research team delineated how ELMO1 facilitates the recognition and engulfment of apoptotic tubular epithelial cells that succumb to nephrotoxic insults. Notably, the enhanced efferocytic activity mediated by ELMO1 curtails the pro-inflammatory milieu within the kidney, mitigating fibrosis and promoting tissue repair. This dual protective mechanism elevates ELMO1 as a molecular sentinel in kidney resilience.

The study took advantage of genetically engineered mouse models deficient in ELMO1 specifically within phagocytic populations. These models exhibited exacerbated renal dysfunction post-nephrotoxin exposure, underscoring the indispensability of ELMO1-driven efferocytosis in renal recovery. Conversely, upregulation of ELMO1 corresponded with improved clearance efficiency and functional outcomes, suggesting that therapeutic modulation of this pathway holds promising potential.

At a molecular level, ELMO1 functions as part of a signaling complex that activates the RAC1 GTPase, a well-known mediator of cytoskeletal remodeling essential for phagocyte engulfment capability. This biochemical cascade allows phagocytes to dynamically respond to apoptotic signals, facilitating the membrane extensions necessary for capturing and internalizing dying cells. The precision of this process is critical in preventing the leakage of intracellular contents that would otherwise ignite damaging inflammatory responses.

Furthermore, the research highlights how impaired efferocytosis can lead to the persistence of apoptotic debris, triggering innate immune activation and perpetuating a cycle of inflammation and cellular injury. This insight provides a mechanistic explanation for the chronic inflammation observed in nephrotoxin-induced AKI, where unresolved apoptotic cells contribute to sustained tissue damage and maladaptive repair.

The clinical implications of these findings are profound. Standard treatment options for AKI remain largely supportive, lacking targeted therapies that can effectively halt or reverse tissue injury. By identifying ELMO1-dependent efferocytosis as a protective mechanism, this study opens avenues for developing pharmacological agents or gene therapies aimed at enhancing efferocytic function in the kidney.

Moreover, the versatility of the efferocytosis pathway extends beyond nephrotoxin-induced injury. Given that efferocytosis is a fundamental biological process across diverse tissues, manipulating ELMO1 activity may also have broader applications in treating other inflammatory and degenerative conditions where apoptotic cell clearance is compromised.

This research also invites a re-examination of patient stratification strategies in AKI treatment trials. Biomarkers related to ELMO1 expression or efferocytic efficiency could serve as predictive indicators of disease progression or therapeutic responsiveness, facilitating personalized medicine approaches in nephrology.

The study’s methodological rigor sets a new benchmark in renal biology research. Combining state-of-the-art imaging techniques, molecular assays, and functional kidney evaluations, the investigators provided compelling, multi-level evidence linking ELMO1 activity to renal health outcomes. Such integrative strategies underscore the importance of cross-disciplinary approaches in unraveling complex pathophysiological processes.

Looking forward, questions remain regarding the regulation of ELMO1 expression under various pathological conditions and how environmental or genetic factors may influence efferocytic capacity in vulnerable patient populations. Future research aimed at dissecting upstream modulators of ELMO1 and downstream effectors of efferocytosis will be essential in translating these findings into tangible clinical interventions.

Equally intriguing is the prospect of combining ELMO1-targeted therapies with other renoprotective strategies, such as anti-inflammatory agents or regenerative medicine approaches, to orchestrate a multifaceted assault on AKI pathogenesis. This multi-pronged approach could amplify therapeutic efficacy and foster kidney repair mechanisms synergistically.

In summary, the elucidation of ELMO1-dependent efferocytosis as a guardian against nephrotoxin-induced acute kidney injury represents a significant stride in nephrology research. By unveiling a novel cellular mechanism that forestalls kidney damage, the study offers renewed hope for millions affected by renal diseases and highlights the intricate balance between cellular clearance and inflammation in organ health.

As the nephrology community grapples with the rising incidence of AKI globally, insights gleaned from this research may catalyze the development of innovative diagnostics and therapeutics, ultimately improving patient outcomes. The notion that harnessing the body’s own efferocytic machinery can shield vital organs from toxic insults underscores the elegant complexity of biological systems and the untapped potential within them.

With ongoing research and clinical validation, ELMO1-centered efferocytosis could emerge as a cornerstone concept in future kidney disease management frameworks. The intersection of cellular biology, molecular medicine, and clinical nephrology embodied in this work exemplifies the transformative power of targeted scientific inquiry.

This pioneering study shines a spotlight on the dynamic interplay between cell death and tissue repair, challenging dogma and inspiring a new era of research aimed at preserving renal function in the face of ever-increasing environmental and pharmaceutical nephrotoxic threats. The path from bench to bedside may be accelerated thanks to these compelling findings, heralding a hopeful chapter for AKI patients worldwide.

Subject of Research: ELMO1-dependent efferocytosis in protection from nephrotoxin-induced acute kidney injury.

Article Title: ELMO1 dependent efferocytosis protects from nephrotoxin induced acute kidney injury.

Article References:
Baffert, B., Cholko, M., Sabapathy, V. et al. ELMO1 dependent efferocytosis protects from nephrotoxin induced acute kidney injury. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03140-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03140-9

Acute kidney injury manifests through a rapid decline in renal function, often triggered by ischemic events, toxic insults, or sepsis. The affected kidney cells undergo complex molecular stress responses, including various regulated cell death programs. Among these, ferroptosis—a recently characterized form of iron-dependent cell death driven by lipid peroxidation—has emerged as a key pathological player. Understanding the regulators of ferroptosis in renal tissue has therefore become a vibrant area of research.

The study led by Li, Lin, Song, and colleagues focuses on the interplay between RSDR and a well-known RNA-binding protein, heterogeneous nuclear ribonucleoprotein K (hnRNPK). Utilizing an integrative approach comprising molecular biology, genetic mouse models, and advanced biochemical assays, the researchers established that RSDR physically associates with hnRNPK to orchestrate a protective response against ferroptotic cell death in kidney tubular cells.

Ferroptosis occurs when imbalance in cellular redox states leads to the accumulation of toxic lipid peroxides, especially in the presence of iron. Central to this process is the enzyme dihydroorotate dehydrogenase (DHODH), which sits at the nexus of mitochondrial metabolism and redox homeostasis. Previously, DHODH was linked mainly to pyrimidine biosynthesis, but recent insights connected it to ferroptosis regulation. This study cements DHODH’s role as the effector molecule controlled by the RSDR-hnRNPK axis during AKI.

Delving deeper, the researchers demonstrated that RSDR modulates the expression and activity of DHODH through its interaction with hnRNPK. The lncRNA acts as a scaffold, recruiting hnRNPK to target transcripts that encode or regulate DHODH, thereby stabilizing the cellular antioxidant defenses. The absence or downregulation of RSDR disrupts this protective mechanism, rendering kidney cells vulnerable to ferroptosis, which exacerbates tissue damage and impairs renal recovery.

The study’s use of genetic mouse models bearing targeted deletions of RSDR provided compelling functional evidence. Mice deficient in RSDR exhibited significantly worse kidney injury following ischemia-reperfusion insults compared to controls. Conversely, therapeutic overexpression of RSDR before injury conferred robust protection, highlighting the translational potential of targeting this lncRNA pathway.

Notably, the manipulation of the RSDR-hnRNPK-DHODH axis did not appear to interfere with other forms of cell death such as apoptosis or necroptosis, underscoring the specificity of this regulatory network in ferroptosis control. This finding suggests that therapeutic strategies could be designed to selectively inhibit ferroptotic damage without unintended effects on other physiological cell death processes.

The implications of these findings extend beyond acute kidney injury. Ferroptosis has been implicated in various pathological contexts including neurodegeneration, cancer, and cardiovascular diseases. The identification of RSDR as a key modulator introduces a paradigm whereby long non-coding RNAs exert fine-tuned regulation over ferroptosis via RNA-binding proteins, which could be harnessed in multiple disease settings.

Mechanistically, the study reveals a delicate balance between mitochondrial metabolic pathways and redox signaling governed by post-transcriptional regulatory networks. The ability of lncRNAs to regulate protein complexes such as hnRNPK that control metabolic enzymes like DHODH exemplifies the emerging complexity of organelle communication and stress adaptation at the RNA level.

Importantly, the authors employed an array of sophisticated molecular techniques, including RNA immunoprecipitation sequencing, fluorescence in situ hybridization, and mitochondrial functional assays, to map the interaction landscape of RSDR. These tools validated the direct binding of RSDR to hnRNPK and the consequent modulation of DHODH stability and activity under oxidative stress conditions.

From a therapeutic perspective, the modulation of lncRNAs presents both opportunities and challenges. The inherent stability and specificity of RNA molecules like RSDR make them attractive targets, yet efficient delivery to renal tissues remains a technical hurdle. Progress in nanoparticle-mediated RNA delivery systems or viral vectors may soon overcome these obstacles, paving the way for clinical translation.

The study also ignites interest in exploring whether similar lncRNA-protein interactions regulate ferroptosis in other organs vulnerable to oxidative damage, such as the brain and liver. Comparative analyses across tissue types might reveal conserved or tissue-specific adaptations, offering a broader understanding of ferroptosis regulation by non-coding RNAs.

Moreover, this discovery adds another dimension to the roles of hnRNPK, previously implicated in transcription, mRNA stability, and DNA repair. Its involvement in fine-tuning ferroptosis via lncRNA scaffolds reveals hnRNPK as a critical node in cell survival networks, potentially providing new targets for drug development.

Given the rising global incidence of AKI due to aging populations and the increasing burden of comorbidities such as diabetes and hypertension, interventions that mitigate ferroptosis-induced cellular damage hold high clinical relevance. The identification of RSDR as an endogenous protector offers hope that harnessing such molecular mechanisms could improve outcomes and reduce the progression to chronic kidney disease and beyond.

This research underscores the paradigm shift driven by investigation into the “dark matter” of the genome—the long non-coding RNAs—once dismissed as transcriptional noise but now recognized as pivotal regulators of physiological and pathological processes. The RSDR-hnRNPK-DHODH axis exemplifies how these molecules integrate metabolic, stress, and death signals in the context of organ injury.

Looking ahead, further studies are warranted to decode the upstream signals that regulate RSDR expression during kidney injury and to map its interaction partners beyond hnRNPK. Such knowledge could reveal additional layers of regulation and identify combinatorial targets for fine-tuning ferroptosis in therapeutic settings.

In summary, this seminal study uncovers a sophisticated molecular mechanism by which the long non-coding RNA RSDR shields kidney cells from ferroptosis during acute injury. Through its interaction with hnRNPK and consequential regulation of DHODH, RSDR emerges as a promising molecular target whose manipulation could transform the landscape of AKI treatment. As the field continues to unravel the complexities of non-coding RNA biology, breakthroughs like this highlight the profound impact of RNA-centered research on understanding and combating human disease.

Subject of Research: Acute kidney injury; long non-coding RNA regulation; ferroptosis; RNA-binding protein hnRNPK; mitochondrial metabolism.

Article Title: The long non-coding RNA RSDR protects against acute kidney injury in mice by interacting with hnRNPK to regulate DHODH-mediated ferroptosis.

Article References:
Li, B., Lin, F., Song, B. et al. The long non-coding RNA RSDR protects against acute kidney injury in mice by interacting with hnRNPK to regulate DHODH-mediated ferroptosis. Nat Commun 16, 7483 (2025). https://doi.org/10.1038/s41467-025-62433-2

Image Credits: AI Generated